MRKAd5 HIV-1 Gag Vaccine (V520) in Subjects With Chronic Hepatitis C (V520-022) (COMPLETED)

A Multicenter, Double-Blind, Randomized, Placebo-Controlled Probe Study With an Additional Open-Label Control Arm to Evaluate the Safety and Immunogenicity of a 3-Dose Regimen of the MRKAd5 HIV-1 Gag Vaccine in Subjects With Chronic Hepatitis C Virus Infection

A Study to assess the general safety and tolerability of the administration of a 3-dose prime/boost regimen of the MRKAd5 HIV-1 gag vaccine (V520) in subjects with chronic hepatitis C virus infection.

Inclusion Criteria:

• Subject who is of reproductive potential agrees to use a acceptable method of birth control through week 52 of the study

Exclusion Criteria:

• Subject weighs less than 110 lbs.
• Subject has received treatment for hepatitis C virus infection in the 3 months before enrollment in this study or is anticipated to begin treatment with in 1 year after enrollment
• Subject has any history of anaphylaxis or allergy to vaccine components
• Subject has any history of anaphylaxis or allergy to Tetanus and Diphtheria Toxoids Adsorbed (Td)
• Subject has clinical signs suggestive of cirrhosis
• Subject has had a liver biopsy showing bridging fibrosis or cirrhosis
• Subject is HBsAg positive
• Subject has other known chronic liver disease
• Subject has evidence of hepatocellular carcinoma on liver biopsy
• Subject has had a liver transplant or is anticipated to have a liver transplant within 1 year of enrollment
• Subject has been vaccinated with a live virus vaccine in the past 30 days
• Subject has been vaccinated with an inactive virus vaccine in the past 14 days
• Female subject is pregnant or breast-feeding, Male subject is planning to impregnate
• Subject has active drug or alcohol abuse
• Subject is at high risk for HIV infection